Nangibotide not checked
Inotrem · LR12 · MOTREM 0.3 mg/kg
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Shock, Septic
- Main trialPhase 2
- “This is a randomized, double-blind, placebo-controlled dose-selection study in which two doses of nangibotide are tested versus placebo.”In the company’s words, NCT04055909 on ClinicalTrials.gov
- Other names
- LR12 · MOTREM 0.3 mg/kg · MOTREM 1 mg/kg · MOTREM 3 mg/kg · MOTREM
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 9 May 2022 | Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock | |
| Phase 2Completed | 13 Jun 2018 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock | |
| Phase 2Completed | 20 May 2022 | Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support | |
| Phase 1Completed | 25 Aug 2016 | Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026